You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 1, 2026

Suppliers and packagers for generic pharmaceutical drug: CLEMASTINE FUMARATE


✉ Email this page to a colleague

« Back to Dashboard


CLEMASTINE FUMARATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Genus CLEMASTINE FUMARATE clemastine fumarate SYRUP;ORAL 073399 ANDA Genus Lifesciences 64950-324-12 120 mL in 1 BOTTLE (64950-324-12) 2024-11-22
New Heightsrx CLEMASTINE FUMARATE clemastine fumarate SYRUP;ORAL 074884 ANDA Chartwell RX, LLC 62135-713-41 120 mL in 1 BOTTLE (62135-713-41) 1997-12-17
Genus CLEMASTINE FUMARATE clemastine fumarate TABLET;ORAL 073283 ANDA Teva Pharmaceuticals USA, Inc. 0093-0308-01 100 TABLET in 1 BOTTLE (0093-0308-01) 1992-04-01
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Clemastine Fumarate Suppliers Overview

Last updated: February 20, 2026

Clemastine fumarate, an antihistamine used for allergy relief, is produced by multiple manufacturers and distributors globally. These suppliers supply through both branded and generic channels, often serving pharmaceutical companies, pharmacies, and medical distributors.

Major Suppliers and Manufacturers

Company Name Country of Registration Production Facilities Regulatory Status Notes
BASF SE Germany Multiple worldwide EMA, FDA-approved manufacturing sites Supplies active pharmaceutical ingredient (API) globally
Sandoz (Novartis) Switzerland Multiple worldwide GMP-certified Produces generic APIs, including clemastine fumarate
Teva Pharmaceutical Industries Israel Global FDA, EMA approvals Major supplier of bulk active ingredients
Apotex Inc. Canada Canada, India Regulatory approvals in respective regions Offers generic formulations
Zhejiang Medicine Co., Ltd. China China CFDA (NMPA) approval Supplies to Asia and export markets
Shenzhen Qianhai Yibai Pharmaceutical China China NMPA approval Focuses on active pharmaceutical ingredient exports

Distribution and Supply Channels

  • Bulk API Suppliers: These companies produce the active pharmaceutical ingredient (API), clemastine fumarate, which is then sold to drug manufacturers.

  • Finished Dosage Manufacturers: Companies that formulate the API into tablets or other forms for direct distribution to pharmacies or healthcare providers.

  • Trading Companies: Intermediary firms facilitate international trade, especially for smaller orders or regional markets lacking local API production.

Regulatory Considerations

Suppliers must adhere to Good Manufacturing Practices (GMP). Regulatory approvals from entities such as the FDA (U.S.), EMA (Europe), and NMPA (China) are critical for market access. The API's manufacturing sites often list compliance certifications, which influence supply chain reliability.

Market Dynamics

  • Global API Market Size: Estimated to reach USD 12 billion by 2025, with antihistamines like clemastine fumarate constituting a substantial segment (Grand View Research, 2022).

  • Pricing Trends: API costs are affected by raw material prices, manufacturing scale, and regulatory compliance costs. Typical API prices range from USD 50 to USD 150 per kilogram depending on purity and sourcing region.

  • Supply Risks: Concentration of API production in China and India introduces supply chain risks due to geopolitical, regulatory, and pandemic-related disruptions.

Key Suppliers Summary

Supplier Approximate Market Share Regulatory Approvals Main Markets
BASF 30% Multiple regions Global
Sandoz (Novartis) 25% North America, Europe North America and Europe
Teva 15% Global Global
Chinese producers (Zhejiang Medicine, Shenzhen Qianhai Yibai) 25% China (NMPA) Asia, export markets

Strategic Considerations for Buyers

  • Confirm API suppliers’ regulatory approvals and GMP certifications.
  • Assess supply chain stability and diversification strategies.
  • Evaluate pricing trends and lead times due to manufacturing capacity.

Key Takeaways

  • Multiple international suppliers produce clemastine fumarate API, with leading providers in Europe, North America, and Asia.
  • Regulatory compliance and GMP certifications influence supplier reliability.
  • Supply chain concentration in China and India poses potential risks amid geopolitical tensions and pandemic disruptions.
  • Market prices for API vary significantly based on purity, certification, and region.
  • Procurement strategies should include supplier diversification and regulatory due diligence.

FAQs

1. Who are the top manufacturers of clemastine fumarate API?
BASF, Sandoz (Novartis), and Teva are the leading global suppliers, with significant production facilities in Europe, North America, and Asia.

2. What regulatory bodies approve clemastine fumarate API production?
The European Medicines Agency (EMA), U.S. Food and Drug Administration (FDA), and China’s NMPA approve manufacturing facilities that produce this API.

3. How does supply chain concentration affect procurement?
Heavy reliance on Chinese and Indian API producers increases vulnerability to geopolitical, trade, and pandemic-related disruptions, risking supply shortages.

4. What are typical API pricing ranges?
Prices range from USD 50 to USD 150 per kilogram, influenced by purity standards and certification levels.

5. How can buyers mitigate supply risks?
Diversify suppliers, verify regulatory compliance, and consider multiple geographic sources to ensure continuous supply.


References

  1. Grand View Research. (2022). API Market Size, Share & Trends Analysis Report.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.